In ICON 7, fully-resected stage III cancers did not have overall survival benefit with bevacizumab. There was also no benefit for clear cell cancers, but the majority of clear cell disease was early stage.

In contrast, there is data from Japan (i.e., JGOG 3022) that advanced stage clear cell ovarian cancer may benefit from adjuvant bevacizumab.